Alder Biopharmaceuticals Inc (NASDAQ:ALDR) Holdings Decreased by Ardsley Advisory Partners LP

Ardsley Advisory Partners LP decreased its holdings in shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) by 33.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 20,000 shares of the biopharmaceutical company’s stock after selling 10,000 shares during the quarter. Ardsley Advisory Partners LP’s holdings in Alder Biopharmaceuticals were worth $235,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Diamond Hill Capital Management Inc. purchased a new position in shares of Alder Biopharmaceuticals during the second quarter valued at $126,000. Fulcrum Capital LLC purchased a new position in shares of Alder Biopharmaceuticals during the second quarter valued at $127,000. Quantamental Technologies LLC purchased a new position in shares of Alder Biopharmaceuticals during the second quarter valued at $156,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Alder Biopharmaceuticals during the second quarter valued at $167,000. Finally, GSA Capital Partners LLP grew its holdings in shares of Alder Biopharmaceuticals by 63.9% during the second quarter. GSA Capital Partners LLP now owns 18,681 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 7,283 shares in the last quarter.

ALDR has been the topic of a number of recent research reports. Svb Leerink initiated coverage on Alder Biopharmaceuticals in a research note on Tuesday, May 28th. They issued an “outperform” rating on the stock. Leerink Swann initiated coverage on Alder Biopharmaceuticals in a research note on Tuesday, May 28th. They issued an “outperform” rating and a $21.00 target price on the stock. Zacks Investment Research upgraded Alder Biopharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $11.00 target price on the stock in a research note on Friday, August 9th. BidaskClub downgraded Alder Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 3rd. Finally, Credit Suisse Group restated a “neutral” rating on shares of Alder Biopharmaceuticals in a research note on Wednesday, July 10th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $16.57.

Shares of NASDAQ ALDR opened at $9.74 on Friday. The business’s 50-day moving average price is $9.39 and its two-hundred day moving average price is $11.51. The company has a debt-to-equity ratio of 1.74, a quick ratio of 8.94 and a current ratio of 8.94. Alder Biopharmaceuticals Inc has a one year low of $8.39 and a one year high of $18.95.

Alder Biopharmaceuticals (NASDAQ:ALDR) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.27. On average, sell-side analysts predict that Alder Biopharmaceuticals Inc will post -4.13 EPS for the current year.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.

Featured Story: What is a closed-end mutual fund (CEF)?

Want to see what other hedge funds are holding ALDR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alder Biopharmaceuticals Inc (NASDAQ:ALDR).

Institutional Ownership by Quarter for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.